CLBS Caladrius Biosciences, Inc.

4.83
+0.33  (7%)
Previous Close 4.50
Open 4.47
Price To book 0.00
Market Cap N/A
Shares 0
Volume 88,856
Short Ratio 0.00
Av. Daily Volume 38,248

SEC filingsSee all SEC filings

  1. S-8 - Securities to be offered to employees in employee benefit plans 17903412
  2. 8-K - Current report 17891245
  3. 8-K - Current report 17855127
  4. 8-K - Current report 17851472
  5. 8-K - Current report 17849842

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 enrollment of first cohort completed September 2016. Second cohort commenced enrollment October 2016. Interim analysis due late 2017 or early 2018.
CLBS03
Type 1 diabetes
Announced January 2016 that Phase 3 trial has been discontinued
CLBS20
Metastatic melanoma

Latest News

  1. Caladrius Biosciences Joins Russell Microcap® Index
  2. Invetech and Caladrius Biosciences Receive 2017 Good Design Award® for Design of a Counterflow Centrifuge Device for use in the Development of Cell Therapies
  3. ETFs with exposure to Caladrius Biosciences, Inc. : June 2, 2017
  4. Caladrius Biosciences to Participate at Upcoming June Conferences
  5. Caladrius Biosciences, Inc. :CLBS-US: Earnings Analysis: Q1, 2017 By the Numbers : May 22, 2017
  6. Caladrius Biosciences Closes the Sale of its Remaining Interest in PCT to Hitachi Chemical for $75 Million
  7. Caladrius Biosciences Announces 2017 First Quarter Financial Results
  8. Caladrius Biosciences to Host 2017 First Quarter Financial Results Conference Call on May 18, 2017 at 5:00 p.m. Eastern Time
  9. Caladrius Biosciences to Participate at Upcoming May Conferences
  10. Shareholder Alert: Monteverde & Associates PC Announces An Investigation Of Caladrius Biosciences, Inc. - CLBS
  11. Caladrius Biosciences to Hold 2017 Annual Stockholder Meeting on May 16
  12. Caladrius Biosciences to Participate at Upcoming April Conferences
  13. Caladrius Biosciences Announces Addition of Four Clinical Sites, Including Joslin Diabetes Center, for the Ongoing Phase 2 Study of CLBS03 in T1D
  14. ETFs with exposure to Caladrius Biosciences, Inc. : March 27, 2017
  15. Caladrius Biosciences, Inc. :CLBS-US: Earnings Analysis: Q4, 2016 By the Numbers : March 21, 2017
  16. Company News for March 20, 2017